Moreover, NBM CD34+ cells exhibit a comparable pattern of mitochondrial dysfunctions to CML CD34+ cells when exposed to ivermectin, while NBM CD34+ cells exhibit a markedly lower sensitivity to the drug than CML CD34+ cells. The gene discussed is CD34; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.